Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies

13Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

The consistency of in vitro drug sensitivity data is of key importance for cancer pharmacogenomics. Previous attempts to correlate drug sensitivities from the large pharmacogenomics databases, such as the Cancer Cell Line Encyclopedia (CCLE) and the Genomics of Drug Sensitivity in Cancer (GDSC), have produced discordant results. We developed a new drug sensitivity metric, the area under the dose response curve adjusted for the range of tested drug concentrations, which allows integration of heterogeneous drug sensitivity data from the CCLE, the GDSC, and the Cancer Therapeutics Response Portal (CTRP). We show that there is moderate to good agreement of drug sensitivity data for many targeted therapies, particularly kinase inhibitors. The results of this largest cancer cell line drug sensitivity data analysis to date are accessible through the online portal, which serves as a platform for high power pharmacogenomics analysis.

Cite

CITATION STYLE

APA

Pozdeyev, N., Yoo, M., Mackie, R., Schweppe, R. E., Tan, A. C., & Haugen, B. R. (2016). Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget, 7(32), 51619–51625. https://doi.org/10.18632/oncotarget.10010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free